SUZHOU CONNECT BIOPHARMACEUTICALS, LTD – Trademark Portfolio
Entity Type: 99
SUZHOU CONNECT BIOPHARMACEUTICALS, LTD holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 1 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include CONNECT BIOPHARMA. The owner is based in Taicang.
East R&D Building, 3rd floor
6 Beijing West Road
Taicang 214500 , CN
Showing of trademarks Trademarks
Trademark Classifications
SUZHOU CONNECT BIOPHARMACEUTICALS, LTD's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does SUZHOU CONNECT BIOPHARMACEUTICALS, LTD have?
SUZHOU CONNECT BIOPHARMACEUTICALS, LTD has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.
What trademark classes does SUZHOU CONNECT BIOPHARMACEUTICALS, LTD file in?
SUZHOU CONNECT BIOPHARMACEUTICALS, LTD files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are SUZHOU CONNECT BIOPHARMACEUTICALS, LTD's most well-known trademarks?
SUZHOU CONNECT BIOPHARMACEUTICALS, LTD's registered trademark portfolio includes well-known marks such as CONNECT BIOPHARMA. These are among 1 currently registered trademark in the portfolio.
What is SUZHOU CONNECT BIOPHARMACEUTICALS, LTD's trademark registration success rate?
SUZHOU CONNECT BIOPHARMACEUTICALS, LTD has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.